TAK1 binding protein 1

  • 文章类型: Journal Article
    干扰素基因(STING)的刺激物从内质网(ER)到ER-高尔基体中间区室(ERGIC)的易位使其活化。然而,STING退出急诊室的调节机制仍然难以捉摸。这里,我们发现STING以TAK1结合蛋白1(TAB1)依赖性方式在STING运输之前诱导转化生长因子β激活激酶1(TAK1)的激活。有趣的是,激活的TAK1直接介导丝氨酸355上的STING磷酸化,从而促进其与STINGER退出蛋白(STEEP)的相互作用,从而促进其低聚和易位到ERGIC进行后续激活。重要的是,通过单磷酰脂质A激活TAK1,TLR4激动剂,在小鼠同种异体移植肿瘤模型中,cGAMP诱导的抗肿瘤免疫依赖于STING磷酸化。一起来看,TAK1通过促进其贩运被确定为STING激活的检查站,为肿瘤联合免疫治疗和干预STING相关疾病提供依据。
    The translocation of stimulator of interferon genes (STING) from the endoplasmic reticulum (ER) to the ER-Golgi intermediate compartment (ERGIC) enables its activation. However, the mechanism underlying the regulation of STING exit from the ER remains elusive. Here, we found that STING induces the activation of transforming growth factor beta-activated kinase 1 (TAK1) prior to STING trafficking in a TAK1 binding protein 1 (TAB1)-dependent manner. Intriguingly, activated TAK1 directly mediates STING phosphorylation on serine 355, which facilitates its interaction with STING ER exit protein (STEEP) and thereby promotes its oligomerization and translocation to the ERGIC for subsequent activation. Importantly, activation of TAK1 by monophosphoryl lipid A, a TLR4 agonist, boosts cGAMP-induced antitumor immunity dependent on STING phosphorylation in a mouse allograft tumor model. Taken together, TAK1 was identified as a checkpoint for STING activation by promoting its trafficking, providing a basis for combinatory tumor immunotherapy and intervention in STING-related diseases.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    破骨细胞的过度骨吸收显著导致破骨细胞相关疾病,例如假体周围骨溶解和骨质疏松症。钛颗粒诱导的颅骨模型中的骨溶解和卵巢切除的小鼠模型中的骨丢失与人类相似;因此,这些模型可用于评估无菌性假体松动和骨质疏松的潜在治疗方法.雷公藤多,它是从雷公藤属的种子中提取的,已经对其抗炎和抗癌的药理作用进行了彻底的研究。然而,雷公藤红素抑制破骨细胞生成的骨代谢机制尚不完全清楚.我们证明,雷公藤红素通过抑制转化生长因子β激活激酶1介导的NF-κB和丝裂原激活蛋白激酶信号通路的激活和下调破骨细胞形成标志物相关基因,在体外抑制核因子κB受体激活配体诱导的破骨细胞形成和骨吸收功能。此外,celastrol也被证明对钛颗粒诱导的骨溶解和小鼠卵巢切除术诱导的骨丢失有益。总的来说,我们的结果表明,雷公藤多酚在预防无菌性假体松动和骨质疏松治疗破骨细胞形成和功能破坏引起的溶骨性疾病中具有良好的应用前景。
    Excessive bone resorption by osteoclasts contributes significantly to osteoclast-related diseases such as periprosthetic osteolysis and osteoporosis. Osteolysis in a titanium particle-induced calvarial model and bone loss in an ovariectomized mice model occurred similarly to those in humans; thus, these models can be used to evaluate potential therapies for aseptic prosthetic loosening and osteoporosis. Celastrol, which is extracted from the seeds of the genus Tripterygium, has been thoroughly investigated for its anti-inflammatory and anti-cancer pharmacological effects. However, the mechanisms involving bone metabolism by which celastrol inhibits osteoclastogenesis are not yet fully understood. We demonstrated that celastrol inhibited the receptor activator of nuclear factor κB ligand-induced osteoclastogenesis and the bone resorptive function of osteoclasts in vitro by inhibiting the activation of transforming growth factor β-activated kinase 1-mediated NF-κB and mitogen-activated protein kinase signaling pathways and downregulating osteoclastogenesis marker-related genes. Furthermore, celastrol was also shown to be beneficial in both the titanium particle-induced osteolysis calvarial and the murine ovariectomy-induced bone loss. Collectively, our results suggested that celastrol is promising for the prevention of aseptic prosthetic loosening and osteoporosis in the treatment of osteolytic diseases induced by disrupted osteoclast formation and function.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    Inflammation of infiltrated macrophages in adipose tissue is a key contributor to the initiation of adipose insulin resistance. These macrophages are exposed to high local concentrations of free fatty acids (FFAs) and can be proinflammatory activated by saturated fatty acids (SFAs). However, the regulatory mechanisms on SFA-induced macrophage inflammation are still elusive. Peroxisome proliferator-activated receptor γ coactivator-1β (PGC-1β) is a member of the PGC-1 family of transcriptional coactivators and has been reported to play a key role in SFAs metabolism and in the regulation of inflammatory signaling. However, it remains unclear whether PGC-1β is involved in SFA-induced macrophage inflammation. In this study, we found that PGC-1β expression was significantly decreased in response to palmitic acid (PA) in macrophages in a dose dependent manner. PGC-1β inhibited PA induced TNFα, MCP-1, and IL-1β mRNA and protein expressions. Furthermore, PGC-1β significantly antagonized PA induced macrophage nuclear factor-κB (NF-κB) p65 and JUN N-terminal kinase activation. Mechanistically, we revealed that TGF-β-activated kinase 1 (TAK1) and its adaptor protein TAK1 binding protein 1 (TAB1) played a dominant role in the regulatory effects of PGC-1β. We confirmed that PGC-1β inhibited downstream inflammatory signals via binding with TAB1 and thus preventing TAB1/TAK1 binding and TAK1 activation. Finally, we showed that PGC-1β overexpression in PA treated macrophages improved adipocytes PI3K-Akt insulin signaling in a paracrine fashion. Collectively, our results uncovered a novel mechanism on how macrophage inflammation induced by SFAs was regulated and suggest a potential target in the treatment of obesity induced insulin resistance.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号